The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.

摘要: Central serous chorioretinopathy (CSC) is characterized by well-demarcated neurosensory retinal detachment in the posterior pole. CSC a self-limiting disease that usually associated with good visual prognosis. In some cases, however, persistent results permanent damage to retina or pigment epithelium [1,2,3,4,5]. Therefore, if disease continues beyond acute phase, active treatment must be considered prevent irreversible function. The pathogenesis of abnormal choroidal circulation and/or barrier function epithelium. Indocyanine green angiography (ICGA) shows dilated vessels and hyperpermeability patients [6]. The recent development enhanced depth image-optical coherence tomography (EDI-OCT) has improved accuracy examinations better quantitative increased reliability [7,8,9]. Several EDI-OCT investigations have analyzed thickness eyes. these reveal greater eyes relative age-matched normal Furthermore, unaffected contralateral also than controls [10,11,12,13,14]. Intravitreal bevacizumab (IVB) injection therapeutic option for chronic CSC. Studies that evaluated efficacy IVB found anatomical outcomes [15,16,17,18,19,20]. However, administration not effective all cases CSC, which necessitates consideration alternative treatments such as focal argon laser photocoagulation photodynamic therapy verteporfin. Inoue et al. [21] demonstrated was without intense hyperfluorescence on late-phase ICGA. Moreover, Jirarattanasopa [22] documented connection between vascular They reported areas ICGA [21,22]. Based observations, we hypothesized responsiveness specific might related findings pretreatment thickness. Given absence prior studies this issue, investigated differences posttreatment subfoveal (SFChT) responders (BevRs) nonresponders (BevNRs) using Heidelberg Spectralis